L
ong-term rhythm control for patients with extended duration of atrial fibrillation (AF) and persistent/ long-standing persistent AF remains challenging. 1 Interventions using catheter ablation, even in the most experienced centers, demonstrated significant recurrence rate and associated morbidity. 2, 3 Therefore, it is important to include surgical intervention to treat AF in these patients if demonstrated to be safe and effective. The cut-and-sew Cox maze procedure for the surgical treatment of AF was introduced in 1987 by Dr James L. Cox. 4 Although found to be highly effective, its widespread adoption was hindered by the lack of a pertinent minimally invasive approach. [5] [6] [7] [8] Today, the cut-and-sew approach of the original maze procedure has evolved to incorporate new ablation technologies and minimally invasive techniques. 9, 10 These modifications have culminated in the procedure that is commonly referred to as the Cox maze III/IV procedure, which is widely considered to be the gold standard for the surgical ablation of AF and includes elimination of the left atrial appendage.
The improvements in surgical ablation techniques and technologies over the past decade have been accompanied by significant increases in the number of stand-alone (ie, not concomitant with other cardiac procedures) surgical ablation procedures performed annually in North America and probably worldwide. 11 Minimally invasive surgical procedures for AF ablation
WHAT IS KNOWN?
• Patients with longer duration of atrial fibrillation and persistent or long-standing persistent atrial fibrillation type can be more challenging to treat. • The Cox maze procedure has been shown to have superior success compared with other beating heart techniques, particularly when performed using a cryothermal energy source.
WHAT THE STUDY ADDS?
• The minimally invasive stand-alone Cox maze procedure for atrial fibrillation can achieve consistently high success rates and extremely low clinical event rates over 5 years of long-term follow-up.
• Appropriate patient selection based on clinical characteristics is imperative to maximize the success of interventions to treat atrial fibrillation.
have been shown to be relatively safe and effective, but many reports are limited to short follow-up periods and only a few follow-up time points. [12] [13] [14] Currently, the vast majority of stand-alone surgical ablation procedures that are performed in North America are limited to the left atrium and beating heart with epicardial ablation only. 11 This trend should be carefully assessed as the efficacy of limited lesion sets and epicardial ablations in stand-alone procedures with or without the combinations of catheter-based endocardial ablation (hybrid procedures) are shown to be less effective and not safer when compared with the minimally invasive biatrial full Cox maze procedures III/IV performed on bypass. 15, 16 A safe and effective minimally invasive approach may have an important role in highly symptomatic patients with persistent and long-standing persistent AF who have either failed catheter ablation or were found not to be good candidates for such an approach because of high failure rates. The purpose of this study was to examine the perioperative safety and 5-year efficacy of the on-pump, minimally invasive through a small right minithoracotomy, stand-alone Cox maze III/IV procedure in a unique group of patients with persistent and long-standing persistent AF.
METHODS
Since 2005, 133 stand-alone, right minithoracotomy, Cox maze III/IV procedures for nonparoxysmal AF based on the Heart Rhythm Society (HRS) guidelines (78% long-standing persistent AF) have been conducted at a single center, including 123 cases performed with cyrothermal energy only. The first 10 procedures in this series were performed using a combination energy of bipolar radiofrequency and cryothermal energy, and these patients did not differ from the remainder of the study sample in this series on preoperative characteristics, including age, body mass index, euroSCORE II, left atrium size, long-standing persistent AF type, duration of AF, female sex, diabetes mellitus, and elective status. Of the Cox maze procedures, a unique subgroup of 68 patients have reached at least 5 years after surgery of prospective rhythm status and clinical course follow-up. This study was approved by our Institutional Review Board (IRB Study No. 06.022 and 12.055), and a waiver of consent was obtained.
Data were collected prospectively before surgery and with follow-up occurring at multiple predefined time points after surgery, including 3, 6, 9, 12, 18, 24 months and then yearly thereafter. Although 5 years after surgery was the primary time point for most analyses, some patients did have followup past 5 years. Success was defined according to the Heart Rhythm Society Guidelines as sinus rhythm without use of class I/III antiarrhythmic medications (AAD) or follow-up catheter ablations and verified using ECG and 24-hour Holter at each time point. 17 A small percentage of patients had rhythm status determined via ECG only, including 18% at 6 months, 13% at 1 year, 8% at 3 years, and 3% at 5 years. Asymptomatic patients off AAD with no documented atrial arrhythmia at 2 years after surgery were offered 5-day continuous Holter monitoring (CardioNet, Malvern, PA) to maximize the capture of silent atrial arrhythmia events. Follow-up rhythm data were available on 95% of eligible patients at 1 year after surgery, 91% of eligible patients at 2 years after surgery, and 86% of eligible patients at 5 years after surgery. Health-related quality of life (HRQL) was captured using the 12-item Short-Form Health Survey (SF-12) assessed preoperatively and at multiple time points after surgery.
18

Medications
The use of AAD and anticoagulant medications after surgery was driven by an institutional protocol. 19 All patients, unless contraindicated, were loaded with amiodarone at 200 mg twice a day for 5 days after surgery followed by 200 mg daily for 3 months to reduce the risk of early atrial arrhythmia recurrence. 20 At 3 months after surgery, if patients were in stable sinus rhythm, the amiodarone was recommended to be discontinued to allow at least 6 weeks off the medication by 6 months of follow-up. Patients with an amiodarone allergy, history of side effects caused by amiodarone, or other clinical contraindications were usually treated with sotalol or flecainide, which was given for 3 months after surgery according to the same principles.
In addition, all patients, unless contraindicated because of high risk for bleeding, were treated with warfarin to maintain international normalized ratio (INR) at 2 to 2.5 or higher in cases such as mechanical valve implantation. At 6 months after surgery, if patients were in stable sinus rhythm off AAD and echocardiography demonstrated well-excluded or excised left atrial appendage and no signs of blood stagnation in the left heart cavities (smoke), anticoagulation was discontinued and patients were maintained on aspirin. Discontinuation of anticoagulation was considered throughout follow-up if patients were qualified, although current guidelines are not specific on discontinuation of anticoagulation after surgical ablation for AF and successful left atrial appendage exclusion or amputation.
Surgical Procedure
The minimally invasive procedure was performed through a right minithoracotomy (5 cm incision) and femoral cannulation with a single arterial cannula and single venous cannula placed through the right atrium into the superior vena cava. The ablation procedure took place as follows: using 3 purse strings on the right atrial free wall, the right-sided maze was conducted with 2 lesions to the tricuspid valve annulus (10 o'clock and 2 o'clock surgeon view), a lesion across the right atrial free wall, lesions to the superior vena cava and the inferior vena cava and across the crista terminalis and the interatrial septum. 21 After performing a vertical atriotomy medially to the right pulmonary veins, energy was applied to complete the box around the pulmonary veins, connect the left upper pulmonary vein with the left atrial appendage endocardially unlike the epicardial lesion in our previous publication, 21 and apply a lesion between the right inferior pulmonary vein to the posterior mitral valve annulus endocardially and epicardially over the coronary sinus. 4, 22 A lesion to connect the box around the pulmonary vein with the left atrial appendage was performed using cryothermal energy. The bipolar radiofrequency lesions were applied using 1 jaw placed epicardially and 1 endocardially simultaneously.
All the cryolesions other than the mitral valve isthmus line were performed endocardially. The coronary sinus lesion is the only epicardial cryolesion in this approach. Conduction block across the pulmonary veins was not tested because this assessment is felt to be unreliable acutely post-ablation after the cryothermal application.
The first 10 procedures in this series were performed using combined energy sources. Bipolar radiofrequency (AtriCure, Inc, Mason, OH) was used to complete the superior vena cava to inferior vena cava line and the counter lesion of the right atrial free wall. The lesions involving the right atrioventricular groove and the tricuspid valve annulus were performed using cryothermal energy (Medtronic, Minneapolis, MN). In regards to left atrial lesions, bipolar radiofrequency was used to connect the right and left superior pulmonary veins and the right and left inferior pulmonary veins. The rest of the procedures (n=123) were performed using cryothermal energy only (Medtronic). The left atrial appendage was excluded with 2 layers of prolene 3-0 suture endocardially in the first 105 patients and with an AtriClip Pro (AtriCure, Inc) through the right minithoracotomy and the transverse sinus. 23 All surgical ablations were performed using Argon-based cryothermal energy (CryoFlex 10 for the first 45 cases and 10s for 78 cases; Medtronic) applied for 2 minutes.
Statistical Analysis
All analyses were conducted using IBM SPSS Statistics Version 24.0 (IBM Corp, Armonk, NY), and a P value of <0.05 2-tailed was considered statistically significant. Continuous data are presented as mean±SD or median [interquartile range (IQR)] and categorical data are presented as frequency (%). Descriptive statistics were used to illustrate the characteristics and outcomes of the full sample (N=133). Kaplan-Meier analyses were conducted to examine the cumulative freedom from embolic stroke and cumulative survival during the first 5 years after surgery. A generalized linear mixed model using multivariable binomial logistic regression with a random intercept was conducted to examine the risk factors for atrial arrhythmia recurrence beyond the blanking period, which included the time points between 6 months and 5 years after surgery. Recurrence was defined at each time point as not in sinus rhythm off AAD or any follow-up cardioversion or ablation interventions for atrial arrhythmias since the previous time point. The fixed-effects factors included in this model were selected a priori based on clinical and theoretical justification and included age, ejection fraction (%), left atrium size (cm), duration of AF (years), type of cryothermal energy probe, and history of previous catheter ablation. Paired-samples t tests were used to evaluate changes over time in HRQL scores.
RESULTS
The mean patient age was 57.3±9.2 years, mean LA size was 4.9±1.1 cm (25% with LA size >5.5 cm), median AF duration was 51 months, 78% had long-standing persistent AF, 22% had persistent AF, and 44% had a previous catheter ablation (Table 1) . There were 24 patients (18%) who had long-standing persistent AF, preoperative AF duration >2 years, and LA size >5.5 cm. The clinical and demographic characteristics of the subsample of patients who reached 5 years after surgery (n=68) were representative of the full sample of patients (Table 1 ) with a mean age of 56.0±9.4 years, mean euroSCORE of 0.8%±0.5%, and 9% female patients.
Safety
In this sample, the minimally invasive stand-alone Cox maze procedure was shown to have acceptable safety as reflected by the low incidence of perioperative morbidity. No conversion to median sternotomy was required. There were no strokes, renal failure, or operative mortality (<30 days). A transient ischemic attack occurred in 1 patient (0.8%) who presented to surgery after 5 attempts of catheter ablation with extensive left atrial scarring. On the basis of this outcome, we changed our policy with such patients and now we resume intravenous heparin as early as possible after the procedure. Reoperation for bleeding occurred in 2 patients (1.5%), no vascular complications, red blood cell transfusion in 4 patients (3%), median [IQR] intensive care unit stay was 23 hours [7-33 hours] , median length of stay was 4 days [3-5.5 days], and the left atrial appendage was excluded in 131 patients (98.5%). New pacemaker implantation for sinus node dysfunc- 
Efficacy
Return to sinus rhythm regardless of interventions at 1, 2, 3, 4, and 5 years after surgery was 93%, 93%, 91%, 91%, and 90%, respectively, and sinus rhythm off AAD at 1, 2, 3, 4, and 5 years after surgery was 88%, 85%, 78%, 81%, and 79%, respectively ( Figure 1 ). Using the HRS Guidelines definition of sinus rhythm off AAD with no follow-up catheter ablations, analyses found that success after a single intervention was 88%, 82%, 76%, 74%, and 73%, respectively, at 1, 2, 3, 4, and 5 years after surgery (Figure 1 ). At 2 years after surgery, a 5-day Holter was offered to all asymptomatic patients with no evidence of atrial arrhythmia. Twenty-five of these patients agreed to participate, of whom 24 (98%) were classified as free from atrial arrhythmia, supporting the 24-hour Holter results. The 1 patient who was defined as having atrial arrhythmia during 5-day Holter monitoring had a single 47 s event that represents a failure per the HRS guidelines, but represents a very low burden with no clinical significance. The patient had long-standing persistent and continuous preoperative AF. Table 2 summarizes atrial arrhythmia captured in all patients at each follow-up time point. These findings may indicate an important reduction in atrial arrhythmia burden, even in patients with captured failure. In addition, using the HRS Guidelines, definition of success as sinus rhythm off AAD at each time point without follow-up catheter ablation was used, and, in 64.8% of patients, atrial arrhythmia was never recorded throughout the entire 5 years of follow-up. During the first Figure 2 ), suggesting an effect of learning curve and influence of new technology over time. Time to first recurrence is shown in Figure 3 , and the KaplanMeier survival analysis found that cumulative freedom from any recurrence was 58.5% at 5 years after surgery. Recurrences between time points (ie, associated with cardioversions) were included in this result even though the HRS Guidelines do not include them in the definition of success.
New Generation Cryothermal Energy Probe
In patients with the new stiffer CryoFlex 10s probe (Medtronic; n=78) that allows better tissue contact, return to sinus rhythm off AAD at 1 and 2 years after 
Follow-Up Events
Most patients were discharged on anticoagulation after surgery (114/133, 86%). During follow-up, the majority of patients were no longer on anticoagulation at 1 year (78%), 2 years (83%), 3 years (79%), and 4 years (73%) after surgery. These discontinuation values were considerably higher (91%, 97%, 96%, and 97%) when evaluating only those patients who were considered safe by their physicians to discontinue anticoagulation at 1, 2, 3, and 4 years after surgery, respectively. In addition, at each of these time points, most patients had discontinued both anticoagulant medications and AAD (75%, 79%, 76%, and 69%, respectively). By 5 years, anticoagulation was discontinued in 56 patients (81%), and the remainder of patients, except for 1, were on anticoagulation with clinical indications (ie, atrial arrhythmia, history of pulmonary embolism, deep vein thrombosis). Thus, 98% of the patients who were considered safe by their physicians to discontinue anticoagulation had done so by 5 years after surgery. In addition, 75% of patients at 5 years had discontinued both anticoagulant medications and AAD. Preoperative median CHA 2 DS 2 -VASc score for the full sample was 1 [0-2] and did not differ significantly between those on and off anticoagulation at 5 years (P=0.107). During a mean follow-up time of 64.8±34.4 months in the full sample (718 patient-years of follow-up), 1 patient experienced an embolic stroke (0.8%) and 2 patients experienced a major bleeding event (1.6%; both on aspirin). Five-year freedom from embolic stroke was 99.2%, and 5-year cumulative survival was 96.1%.
Risk Factors for Recurrence of Atrial Arrhythmia
Significant risk factors for recurrence of atrial arrhythmia >30 s between 6 months and 5 years after surgery were identified by mixed model logistic regression (Table 3) 
Health-Related Quality of Life
For patients with HRQL data before surgery and at 12 months after surgery (n=67), SF-12 scores improved significantly by 12 months for each domain except for bodily pain (Figure 4) 
DISCUSSION
The success of the minimally invasive stand-alone Cox maze III/IV procedure for the surgical ablation of patients with persistent and long-standing persistent AF was consistently high in this unique sample of patients. This approach through a small right minithoracotomy and with the support of the heart-lung machine demonstrated acceptable safety and no operative or 30-day mortality. There were no instances of surgical conversion to median sternotomy, renal failure, embolic stroke, operative, or 30-day mortality, and median length of stay was 4 days. Two patients required reoperation for bleeding with no further consequences. At 5 years after surgery, the procedure showed a relatively high success with 79% in sinus rhythm off AAD, 90% if AAD was allowed, and 73% of the patients were in sinus rhythm off AAD after touch-up catheter ablations. In 64.8% of the patient sample, an atrial arrhythmia recurrence was never captured during 5 years after the procedure. In a large majority of patients (81%), anticoagulation therapy was discontinued by 5 years with extremely low incidences of embolic stroke and of major bleeding.
Patients also experienced significant improvements in quality of life as captured by SF-12 physical and mental HRQL scores. The treatment of AF in patients with persistent and long-standing persistent AF is challenging. [1] [2] [3] The cut-and-sew Cox maze procedure is a biatrial surgical approach that was developed after extensive research and was found to be very effective in treating all patients who present with AF. The original procedure was not widely adopted as it extends the time of surgery, limits the procedure to midsternotomy, and cannot be performed using minimally invasive approaches associated with faster recovery. 4 The recognition of these limitations led to the development of multiple surgical ablation devices that facilitate minimally invasive surgical ablation procedures. 10, 24, 25 In the years since the introduction of minimally invasive approaches for the surgical ablation of AF, many studies have examined the efficacy of these procedures. Most of these reports, however, have been limited to short-term follow-up or have investigated a mixed patient population including patients with paroxysmal AF in the absence of significant comorbid conditions. 26, 27 Few studies have examined the permanence of success of surgical ablation, specifically the Cox maze procedure, over longer follow-up periods. 28, 29 A 2007 study of Cox maze III/ IV outcomes was conducted in 335 patients with a follow-up period of 10 years. 30 In that study, at last follow-up (mean 42±6 months), 88% of patients were free from AF. Their study did not specify the time points at which data were collected or clarify whether information was collected prospectively over time. A more recent study examined 212 patients who had standalone Cox maze III/IV procedures from 1992 through 2010. 29 At a mean follow-up time of 3.6±3.1 years, 93% of patients were free from AF and 82% were not taking AAD. At 10 years, 85% of patients remained free from symptomatic AF. Both studies demonstrated safety of the procedures, but a potential criticism for both is that the studies reported results on historical patients with mixed surgical approaches and there was a lack of standardized reporting as required by the HRS consensus statement. 5 Evidence from the Society of Thoracic Surgeons database demonstrates a significant increase in surgical procedures performed to treat stand-alone AF with the majority of procedures being minimally invasive, confined to the left atrium, and without use of the heart-lung machine. 11 It is clear that the surgical and electrophysiological communities are supportive of such procedures over those performed with the heartlung machine with no clear reasoning. This trend is very important to understand as we look into the future of nonpharmacological treatment of AF. A close look into device-based surgical ablation reveals surgical innovation. However, there are some potential challenges related to the efficacy of devices, lesion sets, and safety. 26, 27 The vast majority of reports on beating heart surgery whether a stand-alone surgical ablation or combined with endocardial catheter ablation have very short follow-up and include mixed populations of AF types with a significant number of paroxysmal AF patients. 31, 32 The most important challenge we have currently is to better understand why we recommend certain surgical procedures over catheter ablation and how to navigate the different types of surgical approaches. Multiple studies from leading centers have demonstrated less than optimal results when catheter ablation was performed in patients with more complex atrial substrate. 2, 3 One of the unanswered questions is whether beating heart surgical ablation procedures with (hybrid) or without endocardial catheter ablation are superior to catheter ablation alone or minimally invasive full Cox maze procedures with the use of cardiopulmonary bypass in terms of efficacy and safety in patients with persistent and long-standing persistent AF. 15 To date, there are only a few head-to-head comparisons between catheter ablation and surgical ablation, but there are no reliable studies to compare all aspects of surgical techniques. 32 A few reviews have demonstrated that beating heart surgical procedures may not be safer than minimally invasive Cox maze procedures. 15, 27 A direct comparison to catheter ablation demonstrated that the convergence procedure had inferior efficacy and safety compared. 16 Although that study is an outlier in the surgical literature it may well indicate some of the potential challenges of beating heart surgery that include highly demanding surgical techniques and the consistent use of unidirectional radiofrequency devices for some or all of the lesions that are notoriously known for inconsistency for transmural lesions. [33] [34] [35] The present study represents the largest series in the literature focused only on patients with history of persistent or long-standing persistent AF (78%) who underwent a minimally invasive stand-alone Cox maze procedure. Eighteen percent of this sample had all 3 important factors related to ablation failure: longstanding persistent AF, longer preoperative AF duration, and larger LA size. Procedural safety was demonstrated by no major procedural or 30-day mortality, stroke, or renal failure. No patients required a conversion to midsternotomy, and median length of stay was 4 days, which was often secondary to anticoagulation with warfarin and awaiting appropriate INR. In our center, we do not use novel oral anticoagulants for the first 3 to 4 weeks after surgical procedures.
When assessing the success of surgical ablation procedures, the following parameters should be measured: freedom from atrial arrhythmia, rate of intermittent recurrence during follow-up, stroke and thromboembolic rates, use of anticoagulation, and quality of life. In this study, it is well demonstrated that a Cox maze procedure, if performed appropriately, can be very effective with 79% of patients in sinus rhythm off AAD at 5 years. Only 1 patient experienced an embolic stroke (0.8%) in 718 patient-years of follow-up with 81% of the patients off oral anticoagulation at 5 years and 98% of those eligible without clinical indications (ie, atrial arrhythmia, history of pulmonary embolism, deep vein thrombosis, etc.). Although current guidelines are not specific on discontinuation of anticoagulation after surgical ablation for AF and successful left atrial appendage exclusion or amputation, in earlier publications, we have shown that oral anticoagulation can be stopped safely in the majority of patients after a successful Cox maze procedure. 36, 37 We attribute this finding to the relatively low recurrence rates of atrial arrhythmias and the successful exclusion of the left atrial appendage. In previous studies, we have found that the CHADS 2 score is a somewhat unreliable tool to guide management of anticoagulation for patients after a Cox maze procedure. 36, 37 There are also no clear and specific guidelines from clinical societies for patients after surgical ablation, and, therefore, an institutional protocol was used to guide treatment in our patients. Oral anticoagulation was considered for discontinuation at 6 months if patients were in sinus rhythm off class I/III AAD for at least 6 weeks, echocardiography (either transthoracic or transesophageal) that was performed in all patients demonstrated that the left atrial appendage was well excluded, and no echogenic smoke was documented in the heart cavity indicating blood flow abnormalities. Patients who were not eligible at 6 months had ongoing assessment for discontinuation during follow-up using the same principles.
The mixed model logistic regression analysis identified longer history of AF as a significant risk factor for arrhythmia recurrence. Previous studies conducted by us and others have pointed out the importance of AF duration as a predictor for recurrence of atrial arrhythmia after surgical ablation. 38, 39 Multiple studies, both on surgical and catheter ablation, highlight the importance of the preprocedural duration of atrial arrhythmia as a significant marker for atrial tissue remodeling and a reliable risk factor for recurrence. This finding may be why in many instances duration of AF has been found to be a more consistent variable compared with type of AF and left atrial size, although these 3 variables are highly associated with one another. 38, 40 The results of our study are comparable with the findings from other investigators and may suggest the importance of early referral for AF intervention to improve success. However, future studies are required to specifically examine whether a strategy of early AF intervention would result in better overall outcomes.
In general, there is relatively little research and development in the field of surgical ablation devices. Therefore, the modification that was made into the CryoFlex surgical catheter (Medtronic) to make it slightly stiffer to improve tissue apposition and contact is unique and important. Although too early to predict long-term success in larger series, our mixed model logistic regression analysis found that the newer generation probe was associated with lower recurrence. The 2-year success rate of 94% off AAD for the newer generation probe is the highest we have ever had and significantly better compared with the results with the softer older generation device of 74% off AAD. Of importance, the probability of follow-up catheter ablation also diminished over the study period and may reflect a learning curve or improved technology as no modifications in the surgical ablation technique were applied.
AF is known to have a major negative impact on quality of life and well-being for patients. 41 The quality of life improvement associated with AF ablation is the result of lower burden of atrial arrhythmia over time with diminished use of antiarrhythmic drugs and oral anticoagulation. In our series, quality of life improved in all but one subscale measured, which indicates the good outcome in all aspects that impact quality of life.
Some limitations of our study should be taken into account. Our results reflect the experience of a single center with a high volume of surgical ablation procedures performed by an experienced surgeon. For this reason, the results on safety and efficacy of the procedure may not be generalizable to all centers. These results may be criticized because long-term assessment was predominantly 24-hour Holter monitoring. Although this detail is a valid point, there is still debate in the literature on what is the best approach to follow patients given the limitations of the implantable event monitoring and battery life that would limit our ability in monitoring beyond 5 years. 42, 43 Our results at 2 years with a 5-day Holter device demonstrating that essentially all asymptomatic patients monitored had no significant atrial arrhythmia events should support our overall findings. We also want to recognize the challenges with the lack of defined policies on event monitor device cost and follow-up processes in the United States. These factors make it challenging to establish different methods of long-term follow-up that will allow incorporation of such devices preoperatively and during follow-up to guide medication discontinuation and follow-up interventions.
CONCLUSIONS
The success of the minimally invasive stand-alone Cox maze procedure for AF was consistently high in this sample of patients, including long-term follow-up at 5 years after surgery. These results support previous studies showing the minimally invasive stand-alone Cox maze procedure to be safe and effective. Continued refinement of decision-making techniques to select appropriate patients for minimally invasive stand-alone surgical ablation is warranted. This study indicated greater success than has been reported in the literature for catheter ablation and beating heart surgical ablation based on ECG and Holter monitoring, although no direct comparison was undertaken in the present study. Therefore, there is a need for a more rigorous direct comparison of all nonpharmacological techniques available to improve our ability to make evidence-based decisions and patient outcomes.
